Entellus Medical, Inc. (NASDAQ:ENTL) was downgraded by research analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday, July 25th.
A number of other research analysts also recently weighed in on the stock. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Entellus Medical in a research report on Wednesday, July 12th. Zacks Investment Research downgraded shares of Entellus Medical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. ValuEngine raised shares of Entellus Medical from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Canaccord Genuity set a $18.00 target price on shares of Entellus Medical and gave the company a “hold” rating in a research report on Monday, May 22nd. Finally, William Blair reissued an “outperform” rating on shares of Entellus Medical in a research report on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company’s stock. Entellus Medical presently has an average rating of “Hold” and a consensus price target of $21.83.
Entellus Medical (ENTL) traded up 2.57% during midday trading on Tuesday, hitting $17.18. 113,450 shares of the company traded hands. Entellus Medical has a 12-month low of $11.47 and a 12-month high of $22.63. The firm’s market capitalization is $376.52 million. The stock’s 50-day moving average is $16.58 and its 200-day moving average is $15.07.
Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.03. The business had revenue of $22.10 million during the quarter, compared to the consensus estimate of $21.87 million. Entellus Medical had a negative net margin of 41.11% and a negative return on equity of 66.04%. The firm’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period last year, the business posted ($0.27) EPS. Analysts anticipate that Entellus Medical will post ($1.62) EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Citadel Advisors LLC purchased a new position in shares of Entellus Medical during the first quarter worth approximately $290,000. Frontier Capital Management Co. LLC purchased a new position in shares of Entellus Medical during the first quarter worth approximately $6,464,000. William Blair Investment Management LLC increased its position in shares of Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 355,388 shares during the period. Renaissance Technologies LLC increased its position in shares of Entellus Medical by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 78,800 shares of the medical technology company’s stock worth $1,495,000 after buying an additional 14,800 shares during the period. Finally, Cortina Asset Management LLC increased its position in shares of Entellus Medical by 22.6% in the first quarter. Cortina Asset Management LLC now owns 412,323 shares of the medical technology company’s stock worth $5,690,000 after buying an additional 75,879 shares during the period. 76.84% of the stock is owned by institutional investors.
About Entellus Medical
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with our FREE daily email newsletter.